Citations

Showing 10 of 108094 citations.

Andrianne Mini-Jupette Graft at the Time of Inflatable Penile Prosthesis Placement for the Management of Post-Prostatectomy Climacturia and Minimal Urinary Incontinence
Yafi, Faysal A. , Andrianne, Robert, Alzweri, Laith , Brady, Jeffrey D., Butcher, Michael, Chevalier, Daniel, DeLay, Kenneth J., Faix, A. , Hatzichristodoulou, Georgios , Hellstrom, Wayne J.G. , Jenkins, Lawrence C. , Köhler, Tobias , Osmonov, Daniar , Park, Sun Hung, Schwabb, M. David, Valenzuela, Robert , Wilson, Steven K. , Renterghem, Koenraad van , Jenkins, Lawrence

Mayo Clinic

The Journal of Sexual Medicine | March 6, 2018 | Volume: 15 | Issue: 5 | Pages: 789-796

10.1016/j.jsxm.2018.01.015 | PMID 29523479 Get It

Abstract Background After radical prostatectomy (RP), erectile dysfunction, often necessitating the need for inflatable penile prosthesis (IPP) insertion, and urinary incontinence and climacturia can ensue. Aim To assess the efficacy and safety of the mini-jupette, a mesh used to approximate the medial aspects of the 2 corporotomies at the time of IPP insertion, for the management of climacturia and urine leakage in patients with minimal incontinence. Methods We conducted a pilot multicenter study of patients with post-RP erectile dysfunction and climacturia and/or mild urinary incontinence (≤2 pads/day [ppd]) undergoing IPP insertion with concomitant placement of a mini-jupette graft. Outcomes Pre- and postoperative erectile function, continence and climacturia, and overall surgical outcomes were assessed. Results 38 patients underwent the mini-jupette procedure. The mean age of the population was 65.3 years (SD = 7.7). 30 had post-RP climacturia and 32 patients had post-RP incontinence (mean = 1.3 ppd, SD = 0.8). 31 patients received Coloplast Titan, 4 received AMS 700 LGX, and 3 received AMS 700 CX IPPs. Mean corporotomy size was 2.9 cm (SD = 1.0). Mean graft measurements were 3.2 cm (SD = 0.9) for width, 3.3 cm (SD = 1.3) for length, and 11.0 cm2 (SD = 5.1) for surface area. At a mean follow-up of 5.1 months (SD = 6.9), there were 5 postoperative complications (13.2%) of which 4 required explantation. Climacturia and incontinence were subjectively improved in 92.8% and 85.7%, respectively. Mean ppd decreased by 1.3 postoperatively. Clinical Implications The Andrianne mini-jupette is a feasible adjunct to IPP placement that can be used for subsets of patients with post-RP climacturia and/or minimal incontinence. Strengths and Limitations Strengths of this study include the novel nature of this intervention, the multi-institutional nature of the study, and the promising results demonstrated. Limitations include the retrospective nature of the study and the heterogeneity of the techniques and grafts used by different surgeons involved. Conclusion Longer follow-up and larger patient cohorts are needed to confirm the long-term safety and benefits of this intervention.
Supporting Our Team Through Creating Awareness
Kasales, Claudia J., Wall, Darci J., Harer, Nora, Goss, Sheryl, Wall, Darci

Mayo Clinic

Ultrasound Quarterly | March 6, 2018 | Volume: 34 | Issue: 2 | Pages: 43-46

10.1097/ruq.0000000000000345 | PMID 29509576 Get It

Abstract Musculoskeletal injuries have been and remain a significant issue for sonographers. Despite its importance, the topic of musculoskeletal injury in sonographers has received little attention in the radiology literature. Our goal is to bring this extremely important issue to the forefront, with the hope of initiating conversations and actions leading to improved workplace practices for sonographers.
Team Approach: Complex Dermal Wound-Healing Utilizing Negative-Pressure Wound Therapy (NPWT) in Orthopaedic Trauma
Green, Tyson , Kavros, Steven J., Springer, Steve, Drez, David, Gremillion, Jared, Kavros, Steven, McCabe, Matthew

Mayo Clinic

JBJS Reviews | March 6, 2018 | Volume: 6 | Issue: 3 | Pages: e1-e1

10.2106/jbjs.rvw.17.00042 | PMID 29509555 Get It

* Repairing skin and soft-tissue loss after severe trauma remains a daunting task because of the complications that arise throughout treatment. Negative-pressure wound therapy (NPWT) has proven to be a useful tool for reducing these complications by facilitating the repair of damaged soft tissue in a variety of scenarios and settings. * The success of NPWT depends on negative pressure, controlling local edema, the removal of inflammatory mediators, revascularization and granulation, and reducing the wound-bed bioburden. * NPWT is a reasonable treatment modality when used appropriately according to recommended indications. * NPWT creates an environment that can help to accelerate healing after devastating soft-tissue loss. * With a high reported rate of success, NPWT can be used in a variety of settings. * NPWT has proven to be useful in conjunction with flaps and grafts to further aid the practitioner in repairing damaged tissue. * NPWT has the potential of eliminating additional surgical procedures and lengthy hospital stays, thus reducing unnecessary costs.
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
Tumlin, James A., Murugan, Raghavan , Deane, Adam M. , Ostermann, Marlies , Busse, Laurence W. , Ham, Kealy R., Szerlip, Harold M. , Prowle, John R. , Bihorac, Azra , Finkel, Kevin W., Zarbock, Alexander , Lynch, S., Jensen, Jeff, Kroll, Stew, Chawla, Lakhmir S. , Tidmarsh, George F., Karvellas, Constantine , Frendl, György , English, Shane , Grimaldi, David , Hite, R. Duncan , Camporota, Luigi , Young, Paul J. , Bihari, Shailesh , Bersten, Andrew D. , Karvellas, Constantine , Kashani, Kianoush , Forni, Lui G. , Lynch, Shannan J., Bellomo, Rinaldo , Bihorac, Azra , Ostermann, Marlies , Deane, Adam M , Young, Paul J , Poissy, Julien

Mayo Clinic

Critical Care Medicine | March 6, 2018 | Volume: 46 | Issue: 6 | Pages: 949-957

10.1097/ccm.0000000000003092 | PMID 29509568 Get It

Objective: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is associated with an unfavorable prognosis. Angiotensin II treatment may help these patients by potentially restoring renal function without decreasing intrarenal oxygenation. We analyzed the impact of angiotensin II on the outcomes of acute kidney injury requiring renal replacement therapy. Design: Post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock 3 trial. Setting: ICUs. Patients: Patients with acute kidney injury treated with renal replacement therapy at initiation of angiotensin II or placebo ( n = 45 and n = 60, respectively). Interventions: IV angiotensin II or placebo. Measurements and Main Results: Primary end point: survival through day 28; secondary outcomes included renal recovery through day 7 and increase in mean arterial pressure from baseline of ≥ 10 mm Hg or increase to ≥ 75 mm Hg at hour 3. Survival rates through day 28 were 53% (95% CI, 38%–67%) and 30% (95% CI, 19%–41%) in patients treated with angiotensin II and placebo ( p = 0.012), respectively. By day 7, 38% (95% CI, 25%–54%) of angiotensin II patients discontinued RRT versus 15% (95% CI, 8%–27%) placebo ( p = 0.007). Mean arterial pressure response was achieved in 53% (95% CI, 38%–68%) and 22% (95% CI, 12%–34%) of patients treated with angiotensin II and placebo ( p = 0.001), respectively. Conclusions: In patients with acute kidney injury requiring renal replacement therapy at study drug initiation, 28-day survival and mean arterial pressure response were higher, and rate of renal replacement therapy liberation was greater in the angiotensin II group versus the placebo group. These findings suggest that patients with vasodilatory shock and acute kidney injury requiring renal replacement therapy may preferentially benefit from angiotensin II.
Not just there to fill space: profound observations on interstitial cells of Cajal in the gastric fundus
Gibbons, Simon J. , Gibbons, S J

Mayo Clinic

The Journal of Physiology | March 6, 2018 | Volume: 596 | Issue: 9 | Pages: 1535-1536

10.1113/jp275923 | PMID 29508395 Get It

Risk of Dental Implant Failure Associated With Medication Use
Revuru, Venkata, Lohse, Christine M. , Carr, Alan B. , Revuru, Venkata S

Mayo Clinic

Journal of Prosthodontics | March 6, 2018 | Volume: 28 | Issue: 7 | Pages: 743-749

10.1111/jopr.12773 | PMID 29508502 Get It

AbstractPurposeThe probability of achieving important clinical outcomes is an increasingly important factor for patients considering various treatment options for tooth loss. For oral reconstruction involving dental implants, the patient‐specific risks of implant failure may be influenced by the patient's medication profile. The purpose of this study was to identify associations between dental implant failure and medication use in a consecutive series of patients seen from October 1983 through December 2014 at the Department of Dental Specialties, Mayo Clinic (Rochester, Minnesota).Materials and MethodsIn this patient‐level analysis, demographic, implant‐specific, and medical profile data were abstracted from a prospective clinical database and individual medical records and used to determine the time to first implant failure. Implant failure‐free survival at the patient level was estimated using the Kaplan‐Meier method. Associations of demographic characteristics and medication use with implant failure were evaluated by using Cox proportional hazards regression models and summarized with hazard ratios and 95% confidence intervals.ResultsIn the 31‐year study period, 6358 patients received their first dental implant (median age, 53 years). The median follow‐up duration of the 5645 patients whose implants did not fail was 5.8 years, and 713 patients had implant failure (median, 0.6 years). All associations were adjusted for age, sex, and era of implantation because these features strongly influence medication use and implant failure. After adjustment, no medication increased the risk of implant failure in the cohort; specifically, medication use at the time of implant placement or starting a medication after implant placement did not increase the risk of implant failure. Among the medications used at the time of implant placement, corticosteroids were associated with a reduced risk of implant failure (hazard ratio, 0.82; 95% CI, 0.67‐0.99; p = 0.04). This association was not seen when corticosteroids were started after implant placement.ConclusionIn the population studied, medication use was not associated with an increased risk of dental implant failure.
The evolution of stem-cell transplantation in multiple myeloma
Mahajan, Sarakshi , Tandon, Nidhi , Kumar, Shaji

Mayo Clinic

Therapeutic Advances in Hematology | March 6, 2018 | Volume: 9 | Issue: 5 | Pages: 123-133

10.1177/2040620718761776 | PMID 29713445 Get It

Autologous stem-cell transplantation (ASCT) remains an integral part of treatment for previously untreated, and may have value in the treatment of relapsed patients with, multiple myeloma (MM). The addition of novel agents like immunomodulators and proteasome inhibitors as induction therapy before and as consolidation/maintenance therapy after ASCT has led to an improvement in complete response (CR) rates, progression-free survival (PFS) and overall survival (OS). With advances in supportive care, older patients and patients with renal insufficiency are now able to safely undergo the procedure. The data concerning the timing of ASCT (early in the disease course or at first relapse), single versus tandem (double) ASCT and the role and duration of consolidation and maintenance therapy post ASCT remain conflicting. This review aims to discuss the evolution of stem-cell transplant over the past 3 decades and its current role in the context of newer, safer and more effective therapeutic agents.
Novel Endovascular Treatment of a Large Basilar Apex Aneurysm With Neck Reconstruction (Barrel Stent) and Coiling Technique: 2-Dimensional Operative Video
Rangel-Castilla, Leonardo , Siddiqui, Adnan H. , Siddiqui, Adnan H , Rangel-Castilla, Leonardo , Davies, Jason M. , Levy, Elad I.

Mayo Clinic

Operative Neurosurgery | March 5, 2018 | Volume: 15 | Issue: 5 | Pages: 603-603

10.1093/ons/opy008 | PMID 29518213 Get It

Return-to-Play for Athletes With Genetic Heart Diseases
Turkowski, Kari L. , Ackerman, Nicholas C., Rohatgi, Ram K., Ackerman, Michael J. , Bos, J. Martijn

Mayo Clinic

Circulation | March 5, 2018 | Volume: 137 | Issue: 10 | Pages: 1086-1088

10.1161/circulationaha.117.031306 | PMID 29507000 Get It